22. August 2013 / by Elke Setzer / 2013
Constance, Germany – In the first twelve months since its market launch in August 2012, nearly 6,000 women have decided for PrenaTest®. It is Europe’s first non-invasive molecular genetic blood test for the determination of fetal trisomies 13, 18 and 21 from maternal blood. The vast majority of the women (approx. 98%) could be relieved by an inconspicuous test result.
Read more
The new PrenaTest®express allows pregnant women at risk to receive the test results within one week
1. Oktober 2013 / by Elke Setzer / 2013
Constance, Germany – With the new PrenaTest®express, LifeCodexx is able to reduce the waiting times for expectant mothers at risk for the test results to a maximum of one week. The PrenaTest®express is the innovative extension of the PrenaTest®, Europe’s first non-invasive molecular genetic blood test to determine fetal trisomies 13, 18 and 21 in the mother’s blood.
Read more
LifeCodexx performs close to 6,000 PrenaTest® analyses in its first year
22. August 2013 / by Elke Setzer / 2013
Constance, Germany – In the first twelve months since its market launch in August 2012, nearly 6,000 women have decided for PrenaTest®. It is Europe’s first non-invasive molecular genetic blood test for the determination of fetal trisomies 13, 18 and 21 from maternal blood. The vast majority of the women (approx. 98%) could be relieved by an inconspicuous test result.
Read more
Improved PrenaTest® provides early knowledge for high risk pregnancies
8. Juli 2013 / by Elke Setzer / 2013
Constance, Germany – PrenaTest®, Europe’s first non-invasive molecular genetic blood test to determine fetal trisomies 13, 18 and 21 in the mother’s blood can now be performed for high risk pregnancies after the ninth week (W 9 + D 0).
Read more
PrenaTest® now detects fetal trisomies 21, 18 and 13
13. Februar 2013 / by Elke Setzer / 2013
Constance, Germany – PrenaTest®, Europe’s first non-invasive molecular genetic blood test to detect fetal trisomy 21 from maternal blood, now also tests for the existence of trisomy 13 and 18 with a high degree of accuracy.
Read more